How cutaneous T-cell lymphoma affects quality of life, and its cost to individual patients and the U.S. healthcare system
Bibliographic record
Abstract
Cutaneous T cell lymphoma (CTCL) is a type of skin cancer that affects nearly 40,000 people in the United States. Unlike other skin cancers, CTCL typically looks like a rash and may cover a small or large amount of skin. Patients with CTCL often experience fear, embarrassment, itchiness, treatment side effects, and financial problems, all of which may reduce quality of life. A research team at Washington University School of Medicine in St. Louis, Missouri, U.S.A. conducted a survey to learn how CTCL affects quality of life and to estimate its cost to individual patients and the U.S. healthcare system. Sixty‐seven CTCL patients completed a widely‐used questionnaire known as the Ontario Health Utilities Index Mark III (HUI3). Scores were used to calculate the average number of quality‐adjusted life years (QALYs) lost by patients with CTCL. A QALY is a way of measuring the burden of a disease, and one QALY equates to one year in perfect health. This number was used to estimate the social and economic burden of CTCL. The study patients were found to have significantly worse quality of life scores compared to results from the U.S. general population. Specifically, CTCL was associated with major increases in emotional suffering and physical pain, along with smaller declines in the ability to speak and walk around. CTCL was estimated to cost $73,389 in the average patient's lifetime and $2.84 billion to the U.S. healthcare system. These findings demonstrate that CTCL is an expensive disease which can significantly reduce quality of life as much as other debilitating health problems such as diabetes and kidney failure. Thus, the authors conclude that effective management of CTCL has the potential to be of great benefit to individual patients as well as the healthcare system. This summary relates to the study: Health‐related quality of life and economic implications of cutaneous T‐cell lymphoma
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".